Mock Call: PI Evaluating a Capital Instrument

The scenario

Dr. Sofia Almeida, an associate professor running a 12-person cancer-genomics lab at a research university. She is sharp, data-driven, and openly skeptical of vendor marketing — she has seen too many spec sheets that do not survive contact with real samples. Her lab does a lot of targeted NGS on challenging clinical material, including degraded FFPE tumor samples. She cares about real bench performance (error rate, coverage uniformity on hard samples), the cost of retraining her postdocs, and whether a purchase can actually clear before her grant money evaporates. She is not hostile — she will engage seriously with evidence — but she will shut down hand-waving fast.

You are calling on Dr. Almeida about the Helixon Q5, Veralux Bioscience's benchtop sequencer. Her lab and the core facility one floor down both run GenoMax, the entrenched competitor platform her postdocs were trained on. She has an R01 renewal with roughly six weeks before the equipment funds must be committed or lost. She is genuinely evaluating whether to buy her own Q5 or simply add capacity on the familiar GenoMax platform. Her lab's real pain point is throughput and quality on FFPE samples, where she suspects her current workflow is costing her failed libraries and re-sequencing. She is interested enough to take the call but expects you to prove the Q5 is worth the switching cost and the risk to her grant timeline. Your job is to discover her actual workflow and bottleneck, present Q5 application evidence honestly, address switching and training risk, and — if you earn it — book an on-site demo on her own samples inside the grant window.

Expect these pushbacks